Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial

PURPOSE: Radiotherapy (RT) plus long-term androgen suppression (AS) are a standard treatment option for patients with high-risk localized prostate cancer. We hypothesized that docetaxel chemotherapy (CT) could improve overall survival (OS) and clinical outcomes among patients with high-risk prostate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Rosenthal, Seth A., Hu, Chen, Sartor, Oliver, Gomella, Leonard G., Amin, Mahul B., Purdy, James, Michalski, Jeff M., Garzotto, Mark G., Pervez, Nadeem, Balogh, Alexander G., Rodrigues, George B., Souhami, Luis, Reaume, M. Neil, Williams, Scott G., Hannan, Raquibul, Horwitz, Eric M., Raben, Adam, Peters, Christopher A., Feng, Felix Y., Shipley, William U., Sandler, Howard M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
RAPID COMMUNICATION
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6506419/
https://ncbi.nlm.nih.gov/pubmed/30860948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02158
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados